Drug Trial Radar · NCT00891202
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)
Last checked: Nov 19, 2026Latest source record: Mar 3, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Nov 2009
Primary completion
Jul 2012
Study completion Jan 2016
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- May 1, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3 study was designed to confirm the efficacy and safety of eliglustat tartrate (Genz-112638) in participants with Gaucher disease Type 1.
Conditions
- Gaucher Disease, Type 1
Interventions
Eliglustat tartrateDrug
PAP: Eliglustat tartrate (ET) capsule 50 mg orally on Day 1 followed by ET 50 mg capsule twice daily (BID) from Day 2 to Week 4, then either ET 50 mg capsule BID (participants with Genz-99067 \[active moiety of ET in plasma\] trough plasma concentration \>=5 ng/mL) or ET 100 mg capsule BID (participants with Genz-99067 trough plasma concentration \<5 ng/mL), up to Week 39. PK assessment at Week 2 used for dose adjustment after Week 4. LTTP: Participants of the eliglustat arm in PAP who completed PAP were included in LTTP and received ET capsule 50 mg BID orally from Day 1 (post Week 39) until Week 43 followed by ET 50 mg or 100 mg capsule BID up to Week 47, then ET 50 mg or 100 mg or 150 mg capsule BID up to Week 312. Dose adjustments at Week 43 and Week 47 were based on Genz-99067 trough plasma concentrations (if trough plasma concentration \<5 ng/mL: next higher dose administered; if \>=5 ng/mL: same dose continued) at Week 41 \& Week 45, respectively.
PlaceboDrug
PAP: Matching placebo capsule once daily on Day 1 followed by matching placebo capsule BID from Day 2 through Week 39. LTTP: Participants of the placebo arm in PAP who completed PAP were included in LTTP and received eliglustat tartrate from Day 1 (post Week 39) up to Week 312. Day 1 (post Week 39) was considered as baseline for LTTP. On Day 1, participants received eliglustat tartrate capsule 50 mg BID orally until Week 43 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 47, then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to Week 312. Dose adjustments at Week 43 and Week 47 were based on Genz-99067 trough plasma concentrations (if trough plasma concentration \<5 ng/mL: next higher dose administered; if \>=5 ng/mL: same dose continued) at Week 41 \& Week 45, respectively.
Primary outcomes
What the sponsor says the trial is designed to measure.
- PAP: Percent Change From Baseline in Spleen Volume (in Multiples of Normal [MN]) at Week 39 of the Primary Analysis Period With Eliglustat Tartrate Treatment as Compared to PlaceboTime frame: PAP Baseline (Day 1), Week 39
Locations
18 sites in 12 countries. Site status is shown where the registry gives one.
UCSF MS Center
San Francisco, California
Yale University School of Medicine
New Haven, Connecticut
Emory University Medical Genetics
Decatur, Georgia
University of Kansas Medical Center, Division of Hematology/Oncology, Dept. of Medicine
Westwood, Kansas
New York University School of Medicine, Neurology Department
New York, New York
Mount Sinai School of Medicine
New York, New York
University hospital "Alexandrovska" Sofia
Sofia, Bulgaria
Sir Mortimer B. Davis - Jewish General Hospital
Montreal, Quebec, Canada
Mount Sinai Hospital and the Samuel Lunenfeld Research Institute
Toronto Ontario, Canada
Hospital de San Jose
Bogotá, Colombia
Christian Medical College Hospital
Vellore, India
Rabin Medical Center, Beilinson Hospital
Petach Tikvah, Israel
Hôtel-Dieu de France University Hospital
Beirut, Lebanon
OCA Hospital
Monterrey, Nuevo Leon, Mexico
Hematology Research Center of Ministry of Healthcare of the Russian Federation
Moscow, Russia
Institut za endokrinologiju
Belgrade, Serbia
Hopital La-Rabta
Tunis, TN, Tunisia
Royal Free Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.